Floatz logo

Toripalimab

Anlotinib

Union Hospital, Tongji Medical College, Huazhong University of Science and Technologymonoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Anlotinib cohort.

Asset / SponsorPhaseRating
Catequentinib
Nanfang Hospital, Southern Medical University
Phase 3BB
Benmelstobart
Nanfang Hospital, Southern Medical University
Phase 3BB
Penpulimab
Degan Lu
Phase 3B
Docetaxel
First People's Hospital of Hangzhou
Phase 2CCC
Carboplatin
Wenjun Cheng
Phase 2CCC

View all 19 →

Same molecule, other indications

Toripalimab is also rated in:

renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
ToripalimabDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →